Antibodies against IL-13 receptor alpha1 and uses thereof

US7807158B2 · kind B2 · utility

Assignee

• Roche Palo Alto LLC · US

Inventors

• Josef Endl · Weilheim, DE
• Maria Elena Fuentes · Sunnyvale, US
• Yvo Graus · Ede, NL
• Adelbert Grossmann · Murnau am Staffelsee, DE
• Sebastian Neumann · Weilheim, DE
• Paul Parren · Utrecht, NL
• Frank Rebers · Utrecht, NL
• Joerg Thomas Regula · Munich, DE
• Ralf Schumacher · Penzberg, DE
• Stefan Seeber · Penzberg, DE
• Jan Olaf Stracke · Penzberg, DE
• Kay-Gunnar Stubenrauch · Frauenfeld, CH
• Jan Van De Winkel · Utrecht, NL
• Martine Van Vugt · Houten, NL
• Sandra Vereecken-Verploegen · Nieuwegein, NL

Key dates

• Filing date: Jan 3, 2006
• Grant date: Oct 5, 2010
• Expiry date: May 2, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The instant specification discloses an antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.